查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
血管炎的全球市場:預測(2022年～2028年)
市場調查報告書
商品編碼
1123152

血管炎的全球市場:預測(2022年～2028年)

Global Vasculitis Market Research and Forecast 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

全球血管炎的市場規模，預計在預測期間內以5.3％的年複合成長率擴大。微創手術的需求高漲，給予該市場影響，成為牽引市場的主要原因之一。在健康領域的支出增加，血管炎的治療研究的活躍，也大幅推動市場成長。

本報告提供全球血管炎市場相關調查，市場概要，以及各類型，各診斷檢查，各治療等級，各終端用戶，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

第3章 競爭情形

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近的開發
  • 主要策略分析
  • COVID-19對主要加入企業的影響

第4章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 機會

第5章 市場區隔

  • 全球血管炎市場，各類型
    • 大血管
    • 中血管
    • 小血管
  • 全球血管炎市場，各診斷檢查
    • 血液檢驗
    • 尿液檢查
    • 影像檢查
    • 其他
  • 全球血管炎市場，各治療等級
    • 皮質類固醇
    • 免疫抑制劑
    • 生技藥品
  • 全球血管炎市場，各終端用戶
    • 醫院，診療所
    • 診斷中心
    • 研究機關
    • 其他

第6章 地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第7章 企業簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • BRISTOL-MYERS SQUIBB CO.
  • Celltrion Healthcare Co.Ltd.
  • ChemoCentryx, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc.
  • Hikma Pharmaceuticals PLC
  • Lilly
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • UCB SA
  • Vifor Pharma Management Ltd.
  • Viatris Inc.
Product Code: OMR2018272

Global Vasculitis Market Research By Type (Large Vessels, Medium Vessels and Small Vessels), By Diagnosis Tests (Blood Test, Urine Test, Imaging Test and Other), By Therapeutic Class (Corticosteroids, Immunosuppressants and Biologics) and By End Users (Hospitals and Clinics, Diagnosis Center, Research Institutes and Other) Forecast 2021-2027

The global vasculitis market is growing at a considerable CAGR of 5.3% during the forecast period. Grown demand for minimally invasive procedures is one of the prime factors affecting and driving the market. Increasing expenditure in the sector of health, growing research, and development in the treatment of vasculitis are also estimated to be the key factors that are contributing significantly towards the growth of the market. However, lack of awareness among people along with cost involved that is high in diagnosis and treatment are major factors constraints that are hindering the growth of the global vasculitis market across the globe.

However, growing advancements in technology and a high number of pipeline products is one of the key factors that are creating opportunity for the market. New product launches in the market are likely to drive the growth of the global vasculitis market. For instance, in July 2020, ChemoCentryx, Inc., had proposed to the US Food and Drug Administration (FDA) for a new drug application (NDA) for avacopan in order to give effective treatment for people suffering from ANCA-associated vasculitis. This will lead to reducing the toxicities related to daily steroid usage for improving the outcome of patients.

Impact of COVID-19 Pandemic on the Global Vasculitis Market

The global vasculitis market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies has disrupted manufacturing and transportation. However, it has generated challenges for the treatment of people suffering from vasculitis.

Segmental Outlook

The market is segmented based on type, diagnosis tests, therapeutic class and end users. Based on type, the market is segmented into large vessels, medium vessels and small vessels. Based on diagnosis tests, blood test, urine test, imaging test and other. By therapeutic class, corticosteroids, immunosuppressants and biologics. Further, by end users, hospitals and clinics, diagnosis center, research institutes and other.

Global Vasculitis Market Share by Therapeutic Class 2020 (%)

Global Vasculitis Market Share by Therapeutic Class

Based on the therapeutic class, corticosteroids are widely being used across the globe. The most frequent type of corticosteroids drug that is suggested to control the inflammation related to vasculitis is named Prednisone. It is one of the glucocorticoid medications that act rapidly for the treatment of vasculitis in all forms in an effective manner. Prednisone is generally given as per the type of vasculitis along with the severity of the vasculitis. Moreover, methylprednisolone is also given to the patients for managing various ANCA-associated vasculitis (AAV).

Regional Outlooks

The global vasculitis market is analyzed based on the geographical regions that are contributing significantly to the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global vasculitis market. Some factors that are boosting the market growth in North America are raising pervasiveness related to vasculitis that is, in turn, growing demand for its treatment. Additionally, increasing R&D activities related to vasculitis along with growing healthcare expenditure in the region are other factors that are promoting the growth of the market. Moreover, in the region of Europe, increased demand for minimally invasive procedures is one of the key factors affecting market growth.

Global Vasculitis Market, by Region 2021-2027

Global Vasculitis Market, by Region

Asia-Pacific will have Considerable Growth in the Global Vasculitis Market

Asia-Pacific region is expected to witness significant growth opportunities for the market. Increasing health awareness among people is likely to drive the growth of the regional market. Additionally, growing cases of microscopic polyangiitis (MPA) in this region especially in China and Japan are impacting the market. Further, growing healthcare expenditure along with increasing government initiatives for the treatment of vasculitis are also impacting the growth of the market.

Market Player Outlook

Key players of the global vasculitis market are BRISTOL-MYERS SQUIBB CO., ChemoCentryx, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., and Novartis AG among others. To survive in the market, these players adopt different marketing strategies such as product launches. For instance, in July 2020, AbbVie Inc. had set forth RINVOQ that is considered to be continuously evaluated across multiple inflammatory diseases for effective outcomes.

In June 2020, F. Hoffmann-La Roche Ltd. had highlighted the phase III IPATential150 study of assessing evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone in which the patients got a decrease in risk that even lead to death.

In March 2020, one of the research-based global biopharmaceutical companies named as AbbVie Inc. had done the acquisition of Allergan plc in order to extend its portfolio.

In March 2019, Bristol-Myers Squibb Co. had done entered into a merger agreement with Celgene Corp. through which Bristol-Myers Squibb Co. will do the acquisition of Celgene Corp at around $74 billion.

In October 2018, F. Hoffmann-La Roche Ltd., had received the US Food and Drug Administration (FDA) for Mabthera/Rituxan (rituximab) in vasculitis that is its two rare forms. Mabthera/Rituxan (rituximab) with conjunction glucocorticoids (GCC) for effective treating of blood vessel disorders that are life-threatening.

In January 2018, Sanofi had done the definitive agreement in order to acquire Ablynx for around $4.6 billion that will strengthen the R&D strategy of Sanofi along with diversifying the rare blood disorders franchise.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global vasculitis market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Vasculitis Industry
  • Recovery Scenario of Global Vasculitis Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Vasculitis Market by Type
    • 5.1.1. Large Vessels
    • 5.1.2. Medium Vessels
    • 5.1.3. Small Vessels
  • 5.2. Global Vasculitis Market by Diagnosis Tests
    • 5.2.1. Blood Test
    • 5.2.2. Urine Test
    • 5.2.3. Imaging Test
    • 5.2.4. Other
  • 5.3. Global Vasculitis Market by Therapeutic Class
    • 5.3.1. Corticosteroids
    • 5.3.2. Immunosuppressants
    • 5.3.3. Biologics
  • 5.4. Global Vasculitis Market by End Users
    • 5.4.1. Hospitals and Clinics
    • 5.4.2. Diagnosis Center
    • 5.4.3. Research Institutess
    • 5.4.4. Other

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. Amgen Inc.
  • 7.3. AstraZeneca
  • 7.4. BRISTOL-MYERS SQUIBB CO.
  • 7.5. Celltrion Healthcare Co.Ltd.
  • 7.6. ChemoCentryx, Inc.
  • 7.7. F. Hoffmann-La Roche Ltd.
  • 7.8. GlaxoSmithKline plc.
  • 7.9. Hikma Pharmaceuticals PLC
  • 7.10. Lilly
  • 7.11. Merck & Co., Inc.
  • 7.12. Novartis AG
  • 7.13. Pfizer Inc.
  • 7.14. Sanofi
  • 7.15. UCB SA
  • 7.16. Vifor Pharma Management Ltd.
  • 7.17. Viatris Inc.

LIST OF TABLES

  • 1. GLOBAL VASCULITIS MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL VASCULITIS MARKET BY TYPE, 2020-2027 ($ MILLION)
  • 3. GLOBAL LARGE VESSELS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL MEDIUM VESSELS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL SMALL VESSELS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL VASCULITIS MARKET BY DIAGNOSIS TESTS, 2020-2027 ($ MILLION)
  • 7. GLOBAL BLOOD TEST MARKET BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL URINE TEST MARKET BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL IMAGING TEST MARKET BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL OTHER MARKET BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL VASCULITIS MARKET BY THERAPEUTIC CLASS, 2020-2027 ($ MILLION)
  • 12. GLOBAL CORTICOSTEROIDS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL IMMUNOSUPPRESSANTS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL BIOLOGICS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL VASCULITIS MARKET BY END USERS, 2020-2027 ($ MILLION)
  • 16. GLOBAL HOSPITALS AND CLINICS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL DIAGNOSIS CENTER MARKET BY REGION, 2020-2027 ($ MILLION)
  • 18. GLOBAL RESEARCH INSTITUTES MARKET BY REGION, 2020-2027 ($ MILLION)
  • 19. GLOBAL OTHER MARKET BY REGION, 2020-2027 ($ MILLION)
  • 20. GLOBAL VASCULITIS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 21. NORTH AMERICAN VASCULITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 22. NORTH AMERICAN VASCULITIS MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 23. NORTH AMERICAN VASCULITIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TESTS, 2020-2027 ($ MILLION)
  • 24. NORTH AMERICAN VASCULITIS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC CLASS, 2020-2027 ($ MILLION)
  • 25. NORTH AMERICAN VASCULITIS MARKET RESEARCH AND ANALYSIS BY END USERS, 2020-2027 ($ MILLION)
  • 26. EUROPEAN VASCULITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 27. EUROPEAN VASCULITIS MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 28. EUROPEAN VASCULITIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TESTS, 2020-2027 ($ MILLION)
  • 29. EUROPEAN VASCULITIS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC CLASS, 2020-2027 ($ MILLION)
  • 30. EUROPEAN VASCULITIS MARKET RESEARCH AND ANALYSIS BY END USERS, 2020-2027 ($ MILLION)
  • 31. ASIA-PACIFIC VASCULITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 32. ASIA-PACIFIC VASCULITIS MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 33. ASIA-PACIFIC VASCULITIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TESTS, 2020-2027 ($ MILLION)
  • 34. ASIA-PACIFIC VASCULITIS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC CLASS, 2020-2027 ($ MILLION)
  • 35. ASIA-PACIFIC VASCULITIS MARKET RESEARCH AND ANALYSIS BY END USERS, 2020-2027 ($ MILLION)
  • 36. REST OF THE WORLD VASCULITIS MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 37. REST OF THE WORLD VASCULITIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TESTS, 2020-2027 ($ MILLION)
  • 38. REST OF THE WORLD VASCULITIS MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC CLASS, 2020-2027 ($ MILLION)
  • 39. REST OF THE WORLD VASCULITIS MARKET RESEARCH AND ANALYSIS BY END USERS, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL VASCULITIS MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL VASCULITIS MARKET SHARE BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL VASCULITIS MARKET, 2021-2027 (%)
  • 4. GLOBAL VASCULITIS MARKET SHARE BY TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL VASCULITIS MARKET SHARE BY DIAGNOSIS TESTS, 2020 VS 2027 (%)
  • 6. GLOBAL VASCULITIS MARKET SHARE BY THERAPEUTIC CLASS, 2020 VS 2027 (%)
  • 7. GLOBAL VASCULITIS MARKET SHARE BY END USERS, 2020 VS 2027 (%)
  • 8. GLOBAL VASCULITIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL LARGE VESSELS MARKET BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL MEDIUM VESSELS MARKET BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL SMALL VESSELS MARKET BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL BLOOD TEST MARKET BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL URINE TEST MARKET BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL IMAGING TEST MARKET BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL OTHER MARKET BY REGION, 2020 VS 2027 (%)
  • 16. GLOBAL CORTICOSTEROIDS MARKET BY REGION, 2020 VS 2027 (%)
  • 17. GLOBAL IMMUNOSUPPRESSANTS MARKET BY REGION, 2020 VS 2027 (%)
  • 18. GLOBAL BIOLOGICS MARKET BY REGION, 2020 VS 2027 (%)
  • 19. GLOBAL HOSPITALS AND CLINICS MARKET BY REGION, 2020 VS 2027 (%)
  • 20. GLOBAL DIAGNOSIS CENTER MARKET BY REGION, 2020 VS 2027 (%)
  • 21. GLOBAL RESEARCH INSTITUTES MARKET BY REGION, 2020 VS 2027 (%)
  • 22. GLOBAL OTHER MARKET BY REGION, 2020 VS 2027 (%)
  • 23. US VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. CANADA VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. UK VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. FRANCE VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. GERMANY VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. ITALY VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. SPAIN VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. REST OF EUROPE VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. INDIA VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. CHINA VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. JAPAN VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 34. SOUTH KOREA VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 35. REST OF ASIA-PACIFIC VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 36. REST OF THE WORLD VASCULITIS MARKET SIZE, 2020-2027 ($ MILLION)